Boehringer returns license of EGFR targeted therapy Olmutinib to Hanmi

Published: 2016-10-05 10:22:01

Updated: 2016-10-05 10:22:01

Over the previous official announcement of the ‘Partnership Agreement before Technology Introduction’ containing terms and conditions that Boehringer Ingelheim has the exclusive right for every indication of ‘HM61713’ in the world except for Korea, China and Hong Kong, process clinical trials, approvals and commercialization and pay the upfront payment of USD 50 million and additional step-by-s...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.